TNF and COVID-19: In addition, further analyses of data from the SECURE-IBD registry indicated that monotherapy with TNF inhibitors may be associated with a lower risk of COVID-19-associated hospitalization or death than other immunomodulatory treatment regimens (methotrexate or azathioprine/6-marcaptopurine with or without TNF inhibitors), with the exception of monotherapy with Janus kinase inhibitors [18].